小分子创新药CDMO市场－全球产业规模、份额、趋势、机会及预测（按产品、阶段类型、客户类型、治疗领域、地区及竞争格局划分，2021-2031年）

全球小分子药物发现 CDMO 市场预计将从 2025 年的 492.6 亿美元成长到 2031 年的 741.8 亿美元，年复合成长率为 7.06%。

该领域由合约组织组成，这些组织协助药物研发公司开发和生产专有的小分子药物。推动该市场发展的关键因素是现代疗法的结构日益复杂，这需要许多生物製药公司本身缺乏的专业化学技能。此外，小分子药物在监管审批流程中的持续主导地位凸显了高效商业化对外部合作伙伴的依赖。药物化学及相关技术协会 (DCAT) 发布的 2025 年数据也印证了这一趋势，报告显示，2024 年美国 FDA核准的新药中，68% 为小分子化合物。

同时，市场扩张的一大障碍是高活性药物原料药的生产能力有限。随着药物研发人员专注于小众、复杂的适应症，专业化、高等级生物安全防护生产设施的需求往往超过现有基础设施。这种先进生产能力需求与现有设施可用性之间的脱节，会造成供应链瓶颈，并延缓创新药物及时上市。因此，缺乏合适的生产设施会对药物从研发到商业性化的整个过程构成风险。

市场驱动因素

新兴的虚拟生技公司采用资产最小化的经营模式，并将研发置于内部生产基础设施之上，外包业务的激增正在重塑市场格局。由于这些创新者缺乏内部生产能力，它们需要与合约研发生产机构（CDMO）建立全面的合作伙伴关係，以支持研发和供应。投资环境的復苏进一步加剧了这种依赖性，为治疗候选药物的研发提供了所需的资金。例如，BioSpace在2025年1月报告称，生物製药投资从去年的233亿美元增加到2024年的260亿美元。这笔资金的涌入直接转化为服务合约的增加，使契约製造製造商成为生技领域的关键产业基础。

同时，肿瘤和某些罕见疾病领域的研发管线不断扩展，推动了专业化生产的需求，尤其是对高活性药物成分（HPAPI）的生产。现代癌症治疗通常使用有毒的小分子药物，这些药物需要先进的密闭技术和复杂的合成过程来确保患者安全，因此，对于药物研发公司而言，找到拥有特定监管专业知识和高等级密闭设施的合作伙伴至关重要。根据Drug Hunter 2025年1月发布的报告，在2024年核准的31种小分子药物中，肿瘤和罕见疾病治疗药物获准数量最多，各有6种。此外，从整体临床开发的角度来看，小分子药物仍占据重要地位，根据Lonza 2025年的报告，小分子药物占所有处于临床开发阶段的分子药物的54%。

市场挑战

高活性药物原料药的产能限制是全球小分子药物研发合约开发与生产（CDMO）市场成长的一大障碍。随着药物研发公司将重点放在复杂肿瘤药物和抗体药物复合体（ADC）的开发上，对高度封闭式生产基础设施的需求呈爆炸性增长。然而，目前的行业产能无法满足这一不断增长的需求，因为只有少数设施具备处理这些高活性化合物所需的严格技术控制和监管合规性。这种短缺导致严重的供应链瓶颈，延长了创新药物的前置作业时间和商业化进程，进而直接限制了市场收入。

根据化学品製造商协会 (SCA) 发布的《2025 年报告》，在接受调查的生产设施中，仅有约三分之一运作GMP 和 FDA 监管标准，这凸显了能够满足这些特殊需求的合规基础设施严重匮乏。因此，合格能的不足限制了契约製造组织订单高价值新计划的能力，并减缓了整体市场扩张。这种结构性短缺迫使企业谨慎分配资源，并凸显了投资建设合规设施以弥合供需缺口的迫切需求。

市场趋势

随着地缘政治紧张局势和《生物安全法案》等立法迫使药品开发商减少对中国服务供应商的依赖，供应链的策略性回流和近岸外包已成为关键趋势。这种结构性调整优先考虑供应链的韧性而非低成本采购，推动了製造外包大规模转移至位于北美和欧洲的合约研发生产机构（CDMO）。这项转型需要大量资金投入，以扩大国内基础设施，从而容纳转移的生产并降低与海外原料药相关的关税风险。根据《今日製造业》2025年7月发布的报告，过去一年，製药公司宣布在美国投资超过2,700亿美元，以降低关税风险并实现国家卫生安全目标。

同时，人工智慧 (AI) 在製程开发和优化中的应用正在透过加速复杂小分子合成的规模化生产，改变整个产业。契约製造正越来越多地采用机器学习演算法来取代传统的经验性试验误法，进行反应监测和产率优化的预测分析。这种数位化转型使製造商能够大幅缩短生产週期并减少材料浪费，从而提高为合作伙伴公司生产小批量、高价值治疗药物的经济效益。根据《健康科技杂誌》(HealthTech Magazine) 2025 年 2 月号报道，辉瑞公司利用人工智慧赋能的生产工艺，实现了 20% 的生产效率提升，充分展现了先进运算策略所能带来的营运效率提升。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章：全球小分子创新者CDMO市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 副产品（低分子量原料药、低分子量药物製剂）
  • 依阶段（临床前、临床、商业化）
  • 依客户类型（製药公司、生技公司）
  • 依治疗领域（心血管疾病、肿瘤、呼吸系统疾病、神经系统疾病、代谢性疾病、感染疾病、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美小分子创新药CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲小分子创新药CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区小分子创新药CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东与非洲小分子创新者CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美小分子创新者CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球小分子创新药CDMO市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Lonza Group AG
• Thermo Fisher Scientific Inc
• Cambrex Corporation
• Catalent, Inc
• Siegfried Holding AG
• Recipharm AB
• Corden Pharma GmbH
• Boehringer Ingelheim GmbH
• Piramal Pharma Solutions
• LABCORP HOLDINGS INC.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Small Molecule Innovator CDMO Market is projected to expand from USD 49.26 Billion in 2025 to USD 74.18 Billion by 2031, reflecting a compound annual growth rate of 7.06%. This sector comprises contract organizations dedicated to facilitating the development and manufacturing of proprietary small molecule drugs for pharmaceutical originators. A primary catalyst for this market is the increasing structural complexity of modern therapeutics, which necessitates specialized chemistry capabilities that many biopharmaceutical companies lack internally. Furthermore, the enduring dominance of small molecule modalities in regulatory pipelines underscores the reliance on external partners for efficient commercialization. Data from the Drug, Chemical & Associated Technologies Association in 2025 highlights this trend, noting that small molecules accounted for 68% of new US FDA drug approvals in 2024.

Conversely, a major impediment to market expansion is the capacity limitation regarding highly potent active pharmaceutical ingredients. As drug developers increasingly focus on niche and complex indications, the demand for specialized high-containment manufacturing facilities frequently exceeds the existing infrastructure. This disparity between the requirement for advanced production capabilities and current facility readiness results in supply chain bottlenecks, potentially delaying the timely delivery of innovative medicines to the market. Consequently, the shortage of appropriate manufacturing assets poses a risk to the efficient progression of therapeutics from development to commercial launch.

Market Driver

The market is being reshaped by a surge in outsourcing from emerging and virtual biotech companies that utilize asset-light models, prioritizing research and development over internal manufacturing infrastructure. Because these innovators lack in-house production capabilities, they require comprehensive partnerships with CDMOs for both development and supply. This dependence is fueled by a rebounding investment climate that supplies the necessary capital to advance therapeutic candidates. For instance, BioSpace reported in January 2025 that biopharma investment rose to $26 billion in 2024 from $23.3 billion the previous year. This influx of funding leads directly to increased service contracts, establishing contract manufacturers as the critical industrial foundation for the biotech sector.

Simultaneously, the expansion of pipelines for oncology and targeted orphan diseases is driving the need for specialized manufacturing, especially for highly potent active pharmaceutical ingredients (HPAPIs). Modern cancer treatments frequently involve toxic small molecules that demand advanced containment and complex synthesis to ensure patient safety, compelling originators to find partners with specific regulatory expertise and high-containment facilities. A January 2025 report from Drug Hunter noted that oncology and rare disease indications led the 31 small molecule approvals in 2024 with six each. Moreover, the broader clinical landscape remains strong, with Lonza reporting in 2025 that small molecules made up 54% of all molecules in clinical development.

Market Challenge

The capacity constraint associated with highly potent active pharmaceutical ingredients stands as a major obstacle to the growth of the Global Small Molecule Innovator CDMO Market. As pharmaceutical originators increasingly prioritize complex oncology therapies and antibody-drug conjugates, the necessity for specialized high-containment manufacturing infrastructure has intensified. However, current industry capabilities are insufficient to meet this rising demand, as few facilities possess the rigorous engineering controls and regulatory compliance required for handling such potent compounds. This deficit creates severe supply chain bottlenecks, causing extended lead times and delaying the timely commercialization of innovative medicines, which directly restricts addressable market revenue.

According to the Society of Chemical Manufacturers & Affiliates, a 2025 report indicated that only approximately one-third of surveyed manufacturing facilities operated under GMP and FDA-regulated standards, underscoring the acute scarcity of compliant infrastructure available to meet these specialized needs. Consequently, this lack of qualified capacity limits the ability of contract organizations to onboard new high-value projects, thereby slowing the overall expansion of the market. This structural deficit forces a careful allocation of resources and highlights the urgent need for investment in compliant facilities to bridge the gap between demand and available supply.

Market Trends

Strategic reshoring and nearshoring of supply chains is emerging as a crucial trend, driven by geopolitical tensions and legislative actions like the BIOSECURE Act that urge pharmaceutical originators to decouple from Chinese service providers. This structural realignment prioritizes supply chain resilience over low-cost sourcing, prompting a massive redirection of manufacturing mandates toward CDMOs located in North America and Europe. This transition necessitates substantial capital allocation for domestic infrastructure expansion to absorb the displaced production volume and mitigate tariff risks associated with foreign-sourced active pharmaceutical ingredients. As reported by Manufacturing Today in July 2025, pharmaceutical firms have announced over $270 billion in US-based investments in the past year to limit tariff exposure and align with national health security goals.

Concurrently, the integration of artificial intelligence in process development and optimization is transforming the sector by accelerating the scale-up of complex small molecule syntheses. Contract organizations are increasingly deploying machine learning algorithms to replace empirical trial-and-error methods with predictive analytics for reaction monitoring and yield optimization. This digital transformation enables manufacturers to drastically reduce cycle times and material waste, thereby enhancing the economic viability of producing low-volume, high-value therapeutics for their partners. According to a February 2025 article in HealthTech Magazine, Pfizer reported that its AI-powered manufacturing processes increased production throughput by 20%, demonstrating the operational efficiency gains achievable through advanced computational strategies.

Key Market Players

• Lonza Group AG
• Thermo Fisher Scientific Inc
• Cambrex Corporation
• Catalent, Inc
• Siegfried Holding AG
• Recipharm AB
• Corden Pharma GmbH
• Boehringer Ingelheim GmbH
• Piramal Pharma Solutions
• LABCORP HOLDINGS INC.

Report Scope

In this report, the Global Small Molecule Innovator CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Small Molecule Innovator CDMO Market, By Product

• Small Molecule API
• Small Molecule Drug Product

Small Molecule Innovator CDMO Market, By Stage Type

• Preclinical
• Clinical
• Commercial

Small Molecule Innovator CDMO Market, By Customer Type

• Pharmaceutical
• Biotechnology

Small Molecule Innovator CDMO Market, By Therapeutic Area

• Cardiovascular disease
• Oncology
• Respiratory disorders
• Neurology
• Metabolic disorders
• Infectious disease
• Others

Small Molecule Innovator CDMO Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Small Molecule Innovator CDMO Market.

Available Customizations:

Global Small Molecule Innovator CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Small Molecule Innovator CDMO Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Small Molecule API, Small Molecule Drug Product)
  • 5.2.2. By Stage Type (Preclinical, Clinical, Commercial)
  • 5.2.3. By Customer Type (Pharmaceutical, Biotechnology)
  • 5.2.4. By Therapeutic Area (Cardiovascular disease, Oncology, Respiratory disorders, Neurology, Metabolic disorders, Infectious disease, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Small Molecule Innovator CDMO Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Stage Type
  • 6.2.3. By Customer Type
  • 6.2.4. By Therapeutic Area
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Small Molecule Innovator CDMO Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Stage Type
      • 6.3.1.2.3. By Customer Type
      • 6.3.1.2.4. By Therapeutic Area
  • 6.3.2. Canada Small Molecule Innovator CDMO Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Stage Type
      • 6.3.2.2.3. By Customer Type
      • 6.3.2.2.4. By Therapeutic Area
  • 6.3.3. Mexico Small Molecule Innovator CDMO Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Stage Type
      • 6.3.3.2.3. By Customer Type
      • 6.3.3.2.4. By Therapeutic Area

7. Europe Small Molecule Innovator CDMO Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Stage Type
  • 7.2.3. By Customer Type
  • 7.2.4. By Therapeutic Area
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Small Molecule Innovator CDMO Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Stage Type
      • 7.3.1.2.3. By Customer Type
      • 7.3.1.2.4. By Therapeutic Area
  • 7.3.2. France Small Molecule Innovator CDMO Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Stage Type
      • 7.3.2.2.3. By Customer Type
      • 7.3.2.2.4. By Therapeutic Area
  • 7.3.3. United Kingdom Small Molecule Innovator CDMO Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Stage Type
      • 7.3.3.2.3. By Customer Type
      • 7.3.3.2.4. By Therapeutic Area
  • 7.3.4. Italy Small Molecule Innovator CDMO Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Stage Type
      • 7.3.4.2.3. By Customer Type
      • 7.3.4.2.4. By Therapeutic Area
  • 7.3.5. Spain Small Molecule Innovator CDMO Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Stage Type
      • 7.3.5.2.3. By Customer Type
      • 7.3.5.2.4. By Therapeutic Area

8. Asia Pacific Small Molecule Innovator CDMO Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Stage Type
  • 8.2.3. By Customer Type
  • 8.2.4. By Therapeutic Area
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Small Molecule Innovator CDMO Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Stage Type
      • 8.3.1.2.3. By Customer Type
      • 8.3.1.2.4. By Therapeutic Area
  • 8.3.2. India Small Molecule Innovator CDMO Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Stage Type
      • 8.3.2.2.3. By Customer Type
      • 8.3.2.2.4. By Therapeutic Area
  • 8.3.3. Japan Small Molecule Innovator CDMO Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Stage Type
      • 8.3.3.2.3. By Customer Type
      • 8.3.3.2.4. By Therapeutic Area
  • 8.3.4. South Korea Small Molecule Innovator CDMO Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Stage Type
      • 8.3.4.2.3. By Customer Type
      • 8.3.4.2.4. By Therapeutic Area
  • 8.3.5. Australia Small Molecule Innovator CDMO Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Stage Type
      • 8.3.5.2.3. By Customer Type
      • 8.3.5.2.4. By Therapeutic Area

9. Middle East & Africa Small Molecule Innovator CDMO Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Stage Type
  • 9.2.3. By Customer Type
  • 9.2.4. By Therapeutic Area
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Small Molecule Innovator CDMO Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Stage Type
      • 9.3.1.2.3. By Customer Type
      • 9.3.1.2.4. By Therapeutic Area
  • 9.3.2. UAE Small Molecule Innovator CDMO Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Stage Type
      • 9.3.2.2.3. By Customer Type
      • 9.3.2.2.4. By Therapeutic Area
  • 9.3.3. South Africa Small Molecule Innovator CDMO Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Stage Type
      • 9.3.3.2.3. By Customer Type
      • 9.3.3.2.4. By Therapeutic Area

10. South America Small Molecule Innovator CDMO Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Stage Type
  • 10.2.3. By Customer Type
  • 10.2.4. By Therapeutic Area
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Small Molecule Innovator CDMO Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Stage Type
      • 10.3.1.2.3. By Customer Type
      • 10.3.1.2.4. By Therapeutic Area
  • 10.3.2. Colombia Small Molecule Innovator CDMO Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Stage Type
      • 10.3.2.2.3. By Customer Type
      • 10.3.2.2.4. By Therapeutic Area
  • 10.3.3. Argentina Small Molecule Innovator CDMO Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Stage Type
      • 10.3.3.2.3. By Customer Type
      • 10.3.3.2.4. By Therapeutic Area

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Small Molecule Innovator CDMO Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Lonza Group AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific Inc
• 15.3. Cambrex Corporation
• 15.4. Catalent, Inc
• 15.5. Siegfried Holding AG
• 15.6. Recipharm AB
• 15.7. Corden Pharma GmbH
• 15.8. Boehringer Ingelheim GmbH
• 15.9. Piramal Pharma Solutions
• 15.10. LABCORP HOLDINGS INC.

16. Strategic Recommendations

17. About Us & Disclaimer